Pfizer Inc. (NYSE:PFE) Shares Bought by Ethos Financial Group LLC

Ethos Financial Group LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 21.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,390 shares of the biopharmaceutical company’s stock after acquiring an additional 2,044 shares during the period. Ethos Financial Group LLC’s holdings in Pfizer were worth $302,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Swedbank AB lifted its holdings in Pfizer by 0.7% in the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after acquiring an additional 37,636 shares during the period. Moloney Securities Asset Management LLC lifted its holdings in Pfizer by 37.8% in the third quarter. Moloney Securities Asset Management LLC now owns 21,086 shares of the biopharmaceutical company’s stock valued at $610,000 after acquiring an additional 5,785 shares during the period. Avidian Wealth Enterprises LLC lifted its holdings in Pfizer by 4.2% in the third quarter. Avidian Wealth Enterprises LLC now owns 22,320 shares of the biopharmaceutical company’s stock valued at $646,000 after acquiring an additional 897 shares during the period. Catalina Capital Group LLC raised its stake in shares of Pfizer by 39.7% during the 3rd quarter. Catalina Capital Group LLC now owns 11,013 shares of the biopharmaceutical company’s stock worth $319,000 after buying an additional 3,127 shares during the last quarter. Finally, Harvest Portfolios Group Inc. raised its stake in shares of Pfizer by 13.1% during the 3rd quarter. Harvest Portfolios Group Inc. now owns 70,900 shares of the biopharmaceutical company’s stock worth $2,052,000 after buying an additional 8,200 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Up 1.0 %

PFE opened at $26.21 on Friday. The firm has a 50 day moving average price of $26.30 and a 200 day moving average price of $27.26. The company has a market cap of $148.51 billion, a PE ratio of 18.59, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company’s revenue was up 24.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.10 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.56%. The ex-dividend date is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is 121.99%.

Insider Buying and Selling

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction on Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on PFE. Citigroup cut their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. UBS Group cut their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Truist Financial cut their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Wolfe Research assumed coverage on Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 price target for the company. Finally, StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.